Jim Cramer on 10 Stocks With The Biggest Declines Last Week

7. Hims & Hers Health, Inc. (NYSE:HIMS)

Number of Hedge Fund Holders: 38

Cramer discussed Hims & Hers Health, Inc.’s (NYSE:HIMS) upcoming challenge now that Ozempic’s shortage is over and said:

“Oh, next, boy, we’re really getting into them, Hims & Hers. Yeah, Hims & Hers Health tumbled 15.8% from Wednesday through Friday. In fact, every penny of that loss was from Friday’s 25% meltdown. Simple story here. This stock had been rallying up 184% year to date as, as of the middle of last week. You know, this is basically an online pharmacy and they’ve been offering cheaper versions of GLP-1 drugs from compounding pharmacies. Those are pharmacies that actually make drugs as opposed to just buying them. They’re allowed to ignore the patent because there’s a shortage of these lifesaving drugs.

But last Friday morning, the FDA announced that the shortage of Novo Nordisk’s Ozempic is over, which means the HIMS gravy train might be over too. Stock’s down big again in after-hours trading after the company reported mixed fourth-quarter results after the close tonight.”

Hims & Hers Health (NYSE:HIMS) provides a telehealth platform offering prescription and over-the-counter health and wellness products, including medication, skincare, sexual health, hair care, and wellness items, along with ongoing support from licensed healthcare professionals.